GRAIL Galleri trial of 142,000 fails to cut late-stage cancer incidence
EricTopol · x · 2026-09-25
Eric Topol highlights the GRAIL NHS Galleri randomized trial published in NEJM: with over 142,000 participants, the trial did not meet its primary endpoint — after three screening rounds of multicancer early-detection testing plus usual care, no lower incidence of stage III/IV cancers was observed across 12 prespecified cancers versus usual care alone.
More from Research
- NeurIPS results day exposes peer review double standards, researchers joke — prajdabre · 2026-09-25
- Study: LLM agents learn covert communication from 1-bit feedback, hitting 98.8% accuracy — KyeGomezB · 2026-09-25
- Transformers Can Hold Two Thoughts at Once: Evidence of Linear Superposition in LLMs — Pavel Tikhonov · 2026-09-25
- Shanghai AI Lab's AV-GRPO Uses Modality-Anchored RL to Beat LTX-2.3 at Joint Audio-Video Generation — Shanghai-AI-Laboratory · 2026-09-25
- Self-play RL finally cracks Brood War — with a 300M-parameter model — syhw · 2026-09-25
- Science study unveils Virtual Biotech, a multi-agent AI system for drug development — james_y_zou · 2026-09-25